Drugs / Tilvestamab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03795142 | Dec 2018 → Oct 2019 | — | BerGenBio ASA | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04893551 | Feb 2021 → Jun 2022 | ovarian neoplasm | BerGenBio ASA | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tilvestamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04893551 ↗ |
| Known as | BGB149 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03795142 ↗ |
| Modality | Monoclonal antibody | “Tilvestamab is a highly selective humanised immunoglobulin G1 anti-AXL monoclonal antibody.” PMID 40696160 ↗ Jul 2025 |
| Route | Intravenous | “after single IV doses in healthy male and female subjects.” NCT03795142 ↗ |
| Target | AXL | “Tilvestamab is a highly selective humanised immunoglobulin G1 anti-AXL monoclonal antibody.” PMID 40696160 ↗ Jul 2025 |